Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 2,761 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Social Media Addiction, Depression, Anxiety, Well-Being, Psychological
Interventions: Mindfulness, Social Media Reduction + Exercise; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Weight Loss Dietary Pattern; Other
Lead sponsor: Colorado State University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 259 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hypertension
Interventions: carvedilol controlled release/lisinopril, lisinopril + placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 76
States / cities: Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more

Conditions: Autism, Sleep Disturbances in Children, Sleep
Interventions: Power Down bedtime manipulation; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: TBI (Traumatic Brain Injury), PTSD
Interventions: V-TRACTS Assessment/Feedback, OPTIONAL Brief Assessment of Thinking, OPTIONAL STEP-Home-Brief, OPTIONAL At-home Exercise Program, OPTIONAL Referral to 12-week STEP-Home, OPTIONAL Clinical Referral; Behavioral
Lead sponsor: VA Boston Healthcare System; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nicotine Dependence
Interventions: Cognitive Behavioural Therapy, Contingency Management, Nicotine Transdermal Patch; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 14 Years to 19 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Interventions: ABBV-400, Itraconazole (ITZ), Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 20
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 15 more

Conditions: HIV Infections
Interventions: Atazanavir, Lopinavir/Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more

Conditions: Obesity, Insulin Resistance, Sedentary Lifestyle
Interventions: Moderate intensity exercise training (MOD-INT), High Intensity exercise training (HI-INT); Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 35 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Erectile Dysfunction
Interventions: Nitric Oxide, Tadalafil, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: RHA Investments Ltd; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity
Interventions: ULTRAFORMER MPT PLUS, Ulthera System; Device
Lead sponsor: CLASSYS Inc.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 273 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Charlotte, North Carolina • Wilmington, North Carolina + 2 more

Conditions: Lymphedema
Interventions: ITP; Other
Lead sponsor: Huntington Memorial Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Cardiovascular Disease (CVD)
Interventions: High-Intensity Functional Training (HIFT), Moderate-Intensity Continuous Training (MICT); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 45 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Nicotine Dependence
Interventions: Aerobic Exercise, Counseling, Nicotine patch; Behavioral · Drug
Lead sponsor: Jasper A. Smits; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infection
Interventions: HAART; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aging, Disease
Interventions: High Intensity Interval training; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 65 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mental Disorder
Interventions: Care Management; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Interventions: None - Observational Study; Other
Lead sponsor: Tempus AI; Industry
Eligibility: 0 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 13
States / cities: Iowa City, Iowa • Bethesda, Maryland • St Louis, Missouri + 9 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 99 Years
Enrollment: 9,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Multiple Locations, New Jersey

Conditions: Tuberculosis
Interventions: Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine; Drug · Dietary Supplement
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 2,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Interventions: TD-1473, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Scottsdale, Arizona • Monroe, Louisiana • Hermitage, Tennessee + 2 more

Conditions: Syncope, Heart Block, Conduction Disorder of the Heart
Interventions: pacemaker, implantable loop recorder; Procedure
Lead sponsor: Canadian Institutes of Health Research (CIHR); Government
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: Low Valence, High Valence; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aphasia, Stroke
Interventions: Adaptive Spacing Condition, High-Item Non-Adaptive Spacing Condition, Low-Item Non-Adaptive Spacing Condition; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Change in Social Media Use and Well-being Among College Students Receiving a One-week Exercise or Mindfulness Intervention

Diet Composition, Weight Control, and Breast Carcinogenesis

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

Differences in Rest, Emotion, and Arousal Modulation in Youth

Translational Research Center for TBI and Stress Disorders: Virtual Assessment of Deployment Trauma and Rehabilitation

Enhancing a High School Based Smoking Cessation Program

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

Effects of Exercise Training Intensity on Fitness and Insulin Sensitivity in African Americans

The Effects of a Nitrate Supplementation on Erectile Function

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP)

High-Intensity Functional Training vs. Moderate-Intensity Continuous Training in Cardiovascular Disease Patients

Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity.

Intermittent Versus Continuous Medication in the Treatment of HIV

Interval Training, Inflammation and Immune Function

Engaging Patients With Mental Disorders From the ED in Outpatient Care

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

TD-1473 for Active Ulcerative Colitis (UC)

Syncope: Pacing or Recording in the Later Years

Psychophysiological Indicators of Performance in Computer-Based Simulation

Adaptive Trial Scheduling in Naming Treatment for Aphasia